Ryan Smith, Global Head of Research & Development at TruDiagnostic, is redefining the future of preventative medicine and longevity through his groundbreaking work in epigenetics and methylation science. After earning a BA in biochemistry from Transylvania University and starting medical school, Ryan shifted his focus to entrepreneurship, founding Tailor Made Compounding, a pharmacy specializing in peptide synthesis. Under his leadership, Tailor Made grew into a healthcare juggernaut, reaching $80 million in revenue within three years. Recognizing the need for more precise tools to measure and reverse the aging process, Ryan transitioned from pharmaceuticals to epigenetic innovation, founding TruDiagnostic in 2020.
As a CLIA-certified lab and health data powerhouse, TruDiagnostic has created the world’s largest private epigenetic database, testing over 15,000 patients and developing cutting-edge algorithms to predict inflammatory markers, disease risks, telomere length, and aging pace. Now as Global Head of Research & Development, Ryan collaborates with leading institutions like Duke, Harvard, Yale, and UCSF to uncover actionable insights from the methylome. Through clinical trials, TruDiagnostic is transforming how we understand and reverse biological aging, cementing Ryan’s role as a trailblazer in precision medicine and longevity science.
